| Rajendra T Gandhi, Md, Llc | |
|
2551 Greenwood Rd Ste 220 Shreveport LA 71103-3985 | |
| (318) 635-9855 | |
| Not Available |
| Full Name | Rajendra T Gandhi, Md, Llc |
|---|---|
| Speciality | Internal Medicine |
| Location | 2551 Greenwood Rd Ste 220, Shreveport, Louisiana |
| Authorized Official Name and Position | Vibha Gandhi (OFFICE MANAGER) |
| Authorized Official Contact | 3186359855 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Rajendra T Gandhi, Md, Llc 2551 Greenwood Rd Ste 220 Shreveport LA 71103-3985 Ph: (318) 635-9855 | Rajendra T Gandhi, Md, Llc 2551 Greenwood Rd Ste 220 Shreveport LA 71103-3985 Ph: (318) 635-9855 |
| NPI Number | 1053595769 |
|---|---|
| Provider Enumeration Date | 12/18/2007 |
| Last Update Date | 12/18/2007 |
| Medicare PECOS PAC ID | 3971685215 |
|---|---|
| Medicare Enrollment ID | O20080125000493 |
News Archive
Chelsea Therapeutics International, Ltd. announced today that it has priced a public offering of approximately 7.14 million shares of its common stock at a price of $4.90 per share which will result in gross proceeds of $35 million. Net proceeds to the company, after underwriting discounts and commissions and expenses, will be approximately $32.8 million.
Students from Trinity College Dublin have successfully created anti-malarial ‘biobricks', which could pave the way for easier and more cost-effective production of the key drug artemisinin.
Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., a Nevada Corporation, has been sued by Teva Women's Health, Inc., in connection with the filing of Watson's Abbreviated New Drug Application (ANDA) for synthetic conjugated estrogens, A, in the 0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg and 1.25 mg tablet strengths. Watson's ANDA is for the generic equivalent of Teva's Cenestin®. The suit was filed on April 23, 2010, in the United States District Court for the District of New Jersey.
This week the U.S. Food and Drug Administration cleared the first nucleic acid amplification In vitro diagnostic (IVD) test that detects Coxiella burnetii, the bacteria that causes Q fever.
Millions of times a year, Americans get prescriptions for a week's worth of steroid pills, hoping to ease a backache or quell a nagging cough or allergy symptoms. But a new study suggests that they and their doctors might want to pay a bit more attention to the potential side effects of this medication.
› Verified 5 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053595769 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | (* (Not Available)) | Primary |
| Provider Name | Rajendra T Gandhi |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1750379608 PECOS PAC ID: 3072695311 Enrollment ID: I20080125000487 |
News Archive
Chelsea Therapeutics International, Ltd. announced today that it has priced a public offering of approximately 7.14 million shares of its common stock at a price of $4.90 per share which will result in gross proceeds of $35 million. Net proceeds to the company, after underwriting discounts and commissions and expenses, will be approximately $32.8 million.
Students from Trinity College Dublin have successfully created anti-malarial ‘biobricks', which could pave the way for easier and more cost-effective production of the key drug artemisinin.
Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., a Nevada Corporation, has been sued by Teva Women's Health, Inc., in connection with the filing of Watson's Abbreviated New Drug Application (ANDA) for synthetic conjugated estrogens, A, in the 0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg and 1.25 mg tablet strengths. Watson's ANDA is for the generic equivalent of Teva's Cenestin®. The suit was filed on April 23, 2010, in the United States District Court for the District of New Jersey.
This week the U.S. Food and Drug Administration cleared the first nucleic acid amplification In vitro diagnostic (IVD) test that detects Coxiella burnetii, the bacteria that causes Q fever.
Millions of times a year, Americans get prescriptions for a week's worth of steroid pills, hoping to ease a backache or quell a nagging cough or allergy symptoms. But a new study suggests that they and their doctors might want to pay a bit more attention to the potential side effects of this medication.
› Verified 5 days ago
News Archive
Chelsea Therapeutics International, Ltd. announced today that it has priced a public offering of approximately 7.14 million shares of its common stock at a price of $4.90 per share which will result in gross proceeds of $35 million. Net proceeds to the company, after underwriting discounts and commissions and expenses, will be approximately $32.8 million.
Students from Trinity College Dublin have successfully created anti-malarial ‘biobricks', which could pave the way for easier and more cost-effective production of the key drug artemisinin.
Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., a Nevada Corporation, has been sued by Teva Women's Health, Inc., in connection with the filing of Watson's Abbreviated New Drug Application (ANDA) for synthetic conjugated estrogens, A, in the 0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg and 1.25 mg tablet strengths. Watson's ANDA is for the generic equivalent of Teva's Cenestin®. The suit was filed on April 23, 2010, in the United States District Court for the District of New Jersey.
This week the U.S. Food and Drug Administration cleared the first nucleic acid amplification In vitro diagnostic (IVD) test that detects Coxiella burnetii, the bacteria that causes Q fever.
Millions of times a year, Americans get prescriptions for a week's worth of steroid pills, hoping to ease a backache or quell a nagging cough or allergy symptoms. But a new study suggests that they and their doctors might want to pay a bit more attention to the potential side effects of this medication.
› Verified 5 days ago
Hs Louisiana, Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1501 Kings Hwy, Suite 5-303, Shreveport, LA 71103 Phone: 904-834-2679 Fax: 904-395-3249 | |
Wk Digestive Disease Consultants Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 2508 Bert Koun Loop, Sutie 304, Shreveport, LA 71118 Phone: 318-671-8880 Fax: 318-671-8879 | |
Andrew Dentino Md And Willis-knighton Medical Center Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2551 Greenwood Rd, Suite 310, Shreveport, LA 71103 Phone: 318-212-8780 Fax: 318-212-8181 | |
Paul S Wilson Md And Willis-knighton Medical Center Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1666 E Bert Kouns Industrial Loop, Suite 230, Shreveport, LA 71105 Phone: 318-212-3970 Fax: 318-212-3975 | |
Maurie Patterson Md And Willis-knighton Medical Center Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 8001 Youree Dr, Suite 400, Shreveport, LA 71115 Phone: 318-212-3456 Fax: 318-212-3885 | |
Raymond A. Coghlan Md And Willis-knighton Medical Center Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2551 Greenwood Rd, Suite 150, Shreveport, LA 71103 Phone: 318-631-9996 Fax: 318-631-9345 | |
Shreveport Family Medicine Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 7505 Pines Road, Suite 1250, Shreveport, LA 71129 Phone: 318-686-3770 Fax: 318-686-3838 |